"Consultation Liaison and Integrated Care for COPD Patients With Psychiatric Co-Morbidity"

Specific Aims

The aim of the proposed research is to evaluate the effectiveness of a holistic disease management paradigm of) that integrates psychiatric and respiratory care (Integrated Psychiatric Consultation Liaison, IPCL) that addresses the high level of psychiatric co-morbidity in COPD patients to improve COPD outcomes.

Methods

Patient population Inpatients and specialist outpatients with established clinical diagnosis of chronic obstructive pulmonary disease (COPD).

Settings

Hospital based specialist outpatient and inpatient acute care and step-down care facilities in four hospitals (NUHS, AH, SGH and CGH) and one community hospital (SLH).

The site PIs from each hospital are Lim Tow Keang (NUHS),Loo Chian Min (SGH),K. Narendran (CGH), Gerald Chua (AH) and Tan Boon Yeow (SLH).

Study design Parallel group, randomized, controlled trial.

Eligible individuals are randomly assigned (1:1 ratio) to either:

1. Integrated Psychiatric Consultation Liaison (IPCL) care (N=450);
2. Usual care. Patients in this group will receive usual standard care (N=450).

Baseline screening and assessment. Prior to randomization to either IPCL or UC arm, COPD patients are screened for anxiety /depression using the Hospital Anxiety and Depression Scale (HADS, see below for details).21.For patients with high HADS scores(≥8), a semi-structured diagnostic assessment will be immediately performed using Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I for DSM-IV22 by an advanced practice nurse (APN) and the provisional diagnosis of anxiety and/or major depressive disorder will be confirmed by a psychiatrist, Cases with significant anxiety or depressive symptomatology that do not meet DSM-IV threshold criteria are classified as subsyndromal cases.

Randomization. After informed consent is signed and patient eligibility is confirmed, the patient will be randomized in a 1:1 ratio to either the intervention arm receiving IPCL care or the control arm receiving usual care. Stratification by center is used to ensure balance between the two arms across centers. Random permuted blocks are used to ensure balance over time. The block length is determined by the study statistician. The patient will be assigned an individual number upon randomization. This assigned randomized number will identify the patient and will be used for all documentation for this patient in this study. The list of randomizations will go through Singapore Clinical Research Institute (SCRI). Randomization may be done via the following options: (i) Direct web randomization: Authorized study center personnel will randomize the patient via a password-protected internet web site available 24 hours a day; (ii) Envelope Randomization: In case of web downtime due to technical error, site personnel may randomize patients using the back-up envelopes that will be provided upon activation of the site.

IPCL Care Group For patients who are randomly allocated to the IPCL arm,

1. Routine active screening and diagnosis of psychiatric co-morbidity using HADS followed by appropriate SCID interview by a trained APN, and confirmation by a consultant psychiatrist, will be performed at 3 monthly intervals during unscheduled and scheduled outpatient consultation or follow up visits and at each hospital admission.
2. The appropriate management of psychiatric and psycho-social problems will be performed by a multi-disciplinary care team that includes the respiratory physician, psychiatrist, advanced practice nurse and nurse clinicians
3. The APN and nurse clinician perform critical roles as case manager and patient educator. Psychoeducation is a critical care process component that will aim to ensure that the majority (over 70%) of COPD patients in the IPCL group with psychological symptoms will accept psycho-social and psychiatric care, in contrast to a large majority of patients who will conventionally refuse care, particularly in the UC group.
4. The treatment of cases will accord with recommended treatment guidelines for anxiety/depression, and individualized for each patient according to a treatment plan drawn up by the psychiatrist, with the agreement of the respiratory physician. Treatment and care management of mild depressive symptomatology, psycho-social problems, or severe major depression and/or anxiety disorder will include appropriate pharmacologic and/or non-pharmacologic therapies (such as cognitive and/or behavioural therapy) and psycho-social support.
5. Where pharmacologic treatment is indicated, the preferred drugs are SSRI antidepressants prescribed according to local standard dosages. The recommended first line of treatment is Fluoxetine, a dose of 20 mg/day or Escitalopram (10 to 20 mg/day). Alternatively, patients who do not respond to Fluoxetine or Escitalopram after 4 weeks, or who have intolerable side effects may be prescribed Venlafaxine XR, 75/mg/day, increased to 150-225 mg/day OR Mirtazapine (15mg/day, increased to 30-45 mg/day). If no response, mood stabilizer or electro convulsive therapy (ECT) or psychosocial intervention will be added on with the medication (Figure 2).
6. Non-drug psychotherapy will be provided either by the psychiatrist or psychological counselor where appropriate (for most patients with only depressive or anxiety symptomatology).
7. The case manager will liaise with medical social worker for financial and other community services support.
8. The nurse educator will provide standard patient education and behavioural modification including information about disease and medications for both COPD and depression, and changing attitudes and behaviour particularly in regard to smoking cessation and medication adherence, and general psycho-social supportive counseling.
9. Appropriate existing and redesigned treatment algorithms and management protocols will be put together and provide a sourcebook for drawing up individual care plans.
10. Routine monitoring and outcomes assessments is integrated as part of IPCL care and performed at 3 or 6 monthly intervals as appropriate: these include perceived symptoms of breathlessness, exercise tolerance, spirometric measurement (12 month), smoking cessation, HADS, SGRQ quality of life, acute COPD exacerbations, rehospitalization(s), emergency department visits, and unscheduled physician visits etc.(see schedule).
11. Ad hoc follow up visits are scheduled at any appropriate times for therapeutic monitoring and responses.
12. The management of COPD will proceed as usual according to standard clinical practice for COPD.

Usual Care Control Group. For patients who are randomly allocated to the UC Control Group,

1. The presence of psychiatric co-morbidity will be identified under standard conditions by usual care team, with the appropriate psychiatric consultation-liaison referrals and treatment effected as deemed necessary.
2. Treatment and care management of psychiatric and psycho-social problems will include appropriate pharmacologic and/or non-pharmacologic therapies and psycho-social support, in accordance with standard recommended guidelines and practices for both COPD and anxiety/depression.
3. The assessment of trial outcomes performed at 3 or 6 monthly intervals as appropriate (perceived symptoms of breathlessness, exercise tolerance, spirometric measurement, smoking cessation, HADS, SGRQ quality of life, acute COPD exacerbations, rehospitalization(s), emergency department visits, and unscheduled physician visits etc.) is also performed, but is not an integral part of Usual Care.
4. Ad hoc outpatient follow up visits are scheduled at any appropriate times for therapeutic and other care monitoring and responses.
5. The management of COPD will proceed as usual according to standard clinical practice for COPD.

To mimic prevailing conditions of healthcare financing and delivery, payments for referrals to hospital psychiatrists for treatment, drugs and psychotherapy, regardless of allocation to IPCL or UC group, will be borne by the patients using existing avenues of health service financing (Medisave, Medishield, and/or out-of-pockets) as appropriate.

Trial related scheduled assessments of outcome measures All participants in both IPCL and UC control arms will be assessed at baseline, 3 months, 6 months, 9 months and 12 months for the following trial related outcomes. We define loss to follow-up (LTFU) as incomplete ascertainment of the primary outcome for subjects randomized in the trial. Operationally, LTFU is defined as absence from at least 2 consecutive assessments (>6 months).

Statistical Analysis

Primary effectiveness end-points

• HADS score
• Breathlessness (MRC Index)
• Six-minutes walking distance
• Borg's scale
• FEV1, FEV1/FVC, PEFR, SpO2
• BODE Index
• Smoking quit rates
• Functional health and quality of life (SGRQ scores, CAT score, quality-adjusted life years (QALY))
• Acute COPD exacerbations
• Emergency department visits
• Unscheduled physician visits
• Re-hospitalization(s)

Secondary effectiveness end points:

• Resource use and direct costs of care:
• 1. Resource use include inpatient service use (No. of times hospitalized and total days in hospital) , outpatient service use (physician visits consisting of GP visits and specialist visits,) and medication use( usage of any or specific drug classes)
• 2. Direct costs of care include costs for outpatient medical and mental health care, inpatient medical and mental health services and medication.
• Mortality
• COPD medication adherence
• Psychiatric medication adherence